Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia

Completed · Not applicable

Conditions studied: Gram-negative Bacteremia

In brief

RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1. Standard culture and antimicrobial susceptibility testing (AST); or 2. Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)

Key facts

Study ID

NCT03218397

Run by

Duke University

People needed

500

Starts

2017-10-09

Expected to finish

2018-11-30

Last updated by the study team

2019-11-26

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive blood culture with Gram stain showing GNB identified during local laboratory business hours.

You may not qualify if…

• Identification of GNB outside of local laboratory business hours (e.g. whenever laboratories are staffed to perform both rapid testing and routine testing)
• Positive blood culture for GNB at the same institution within prior 7 days (if known at the time of randomization).
• Deceased at the time of randomization.
• GNB plus gram-positive organism, gram-negative cocci, and/or yeast detected on Gram stain
• Previous enrollment in this study
• No Minnesota research authorization (Rochester site only)

Where it is running

• University of California, Los Angeles — Los Angeles, California, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.